A 53-year-old with T2DM (A1c 7.4%) and CKD asks about GLP‑1 RA vs SGLT2. He already takes an SGLT2 inhibitor. Next best agent for ASCVD risk reduction...

Question

A 53-year-old with T2DM (A1c 7.4%) and CKD asks about GLP‑1 RA vs SGLT2. He already takes an SGLT2 inhibitor. Next best agent for ASCVD risk reduction?

Accepted Answer

Add GLP‑1 RA with proven CV benefit

Answer

DPP-4 inhibitor

Answer

Sulfonylurea

Answer

Thiazolidinedione

Answer

Basal insulin

us-abim MCQ (SBA): Combination cardiometabolic therapy

A 53-year-old with T2DM (A1c 7.4%) and CKD asks about GLP‑1 RA vs SGLT2. He already takes an SGLT2 inhibitor. Next best agent for ASCVD risk reduction?